This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed Waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma.

Inclusion Criteria:

• Age of 19 or older
• Newly diagnosed Waldenstrom's macroglobulinemia or lymphoplasmacytic lymphoma
• Previously untreated with chemotherapy
• ECOG performance status of 2 or lesser
• Peripheral blood white blood cell count ≥ 3,500/uL
• Peripheral blood neutrophil count ≥ 1,000/uL
• Peripheral blood platelet count ≥ 20,000/uL
• Peripheral blood hemoglobin ≥ 6.0g/dL
• Serum total bilirubin ≤ 2.0 mg/dL
• Serum aspartate aminotransferase ≤ 2.5 x (upper normal limit)
• Serum alanine aminotransferase ≤ 2.5 x (upper normal limit)

Exclusion Criteria:

• Diagnosed with other malignancy within 5 years before enrollment
• Prior hematopoietic stem cell transplantation
• Prior organ transplantation
• Uncontrolled central nervous system involvement
• Congenital immunodeficiency
• Acquired immune deficiency syndrome (AIDS)
• Pregnancy
• Uncontrolled epilepsy
• Uncontrolled psychological disease
• Peripheral neuropathy of grade 3 or higher

IPD regarding participant demographics, study treatment, response, survival, and adverse events will be shared after publishment of the study results.

IPD will be shared after the publication of the study results without time limit.

IPD will be shared only for the research purpose.